{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:21:35Z","timestamp":1792707695061,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00259-025-07457-y","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T07:21:40Z","timestamp":1754464900000},"page":"518-530","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Potential utility of plasma pTau217 for assessing amyloid and tau biomarker profiles"],"prefix":"10.1007","volume":"53","author":[{"given":"Daeun","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyemin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heejin","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungmin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Gonzalez-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hye","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihwan","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duk L.","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hoon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko Woon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeo Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeshin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Young","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na Yeon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Hyun","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Pyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4262-1468","authenticated-orcid":false,"given":"Sang Won","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the K-ROAD study groups","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"7457_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer\u2019s association guidelines for the neuropathologic assessment of alzheimer\u2019s disease. Alzheimers Dement. 2012;8:1\u201313. https:\/\/doi.org\/10.1016\/j.jalz.2011.10.007.","journal-title":"Alzheimers Dement"},{"key":"7457_CR2","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.jalz.2015.05.018","volume":"11","author":"DR Thal","year":"2015","unstructured":"Thal DR, Beach TG, Zanette M, Heurling K, Chakrabarty A, Ismail A, et al. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic alzheimer\u2019s disease: specific detection of advanced phases of amyloid-\u03b2 pathology. Alzheimers Dement. 2015;11:975\u201385. https:\/\/doi.org\/10.1016\/j.jalz.2015.05.018.","journal-title":"Alzheimers Dement"},{"key":"7457_CR3","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","volume":"11","author":"O Sabri","year":"2015","unstructured":"Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in alzheimer\u2019s disease: phase 3 study. Alzheimers Dement. 2015;11:964\u201374. https:\/\/doi.org\/10.1016\/j.jalz.2015.02.004.","journal-title":"Alzheimers Dement"},{"key":"7457_CR4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","volume":"77","author":"AS Fleisher","year":"2020","unstructured":"Fleisher AS, Pontecorvo MJ, Devous MD, Sr., Lu M, Arora AK, Truocchio SP, et al. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of alzheimer disease neuropathologic changes. JAMA Neurol. 2020;77:829\u201339. https:\/\/doi.org\/10.1001\/jamaneurol.2020.0528.","journal-title":"JAMA Neurol"},{"key":"7457_CR5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"key":"7457_CR6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/s1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, et al. Blood-based biomarkers for alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol. 2022;21:66\u201377. https:\/\/doi.org\/10.1016\/s1474-4422(21)00361-6.","journal-title":"Lancet Neurol"},{"key":"7457_CR7","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","volume":"3","author":"O Hansson","year":"2023","unstructured":"Hansson O, Blennow K, Zetterberg H, Dage J. Blood biomarkers for alzheimer\u2019s disease in clinical practice and trials. Nat Aging. 2023;3:506\u201319. https:\/\/doi.org\/10.1038\/s43587-023-00403-3.","journal-title":"Nat Aging"},{"key":"7457_CR8","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.1002\/alz.13455","volume":"19","author":"K Blennow","year":"2023","unstructured":"Blennow K, Galasko D, Perneczky R, Quevenco FC, van der Flier WM, Akinwonmi A, et al. The potential clinical value of plasma biomarkers in alzheimer\u2019s disease. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc. 2023;19:5805\u201316. https:\/\/doi.org\/10.1002\/alz.13455.","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"key":"7457_CR9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3988\/jcn.2022.18.4.401","volume":"18","author":"SA Park","year":"2022","unstructured":"Park SA, Jang YJ, Kim MK, Lee SM, Moon SY. Promising blood biomarkers for clinical use in alzheimer\u2019s disease: A focused update. J Clin Neurol. 2022;18:401\u20139.","journal-title":"J Clin Neurol"},{"key":"7457_CR10","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Bali D, Ashton NJ, Barth\u00e9lemy NR, Vanbrabant J, Stoops E, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal alzheimer\u2019s disease. Brain. 2023;146:1592\u2013601. https:\/\/doi.org\/10.1093\/brain\/awac333.","journal-title":"Brain"},{"key":"7457_CR11","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/alz.12841","volume":"19","author":"NJ Ashton","year":"2023","unstructured":"Ashton NJ, Puig-Pijoan A, Mil\u00e0-Alom\u00e0 M, Fern\u00e1ndez-Lebrero A, Garc\u00eda-Escobar G, Gonz\u00e1lez-Ortiz F, et al. Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated Tau immunoassays. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc. 2023;19:1913\u201324. https:\/\/doi.org\/10.1002\/alz.12841.","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"key":"7457_CR12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault J, Vermeiren M, Servaes S, Tissot C, Ashton NJ, Benedet AL, et al. Association of phosphorylated Tau biomarkers with amyloid positron emission tomography vs Tau positron emission tomography. JAMA Neurol. 2023;80:188\u201399. https:\/\/doi.org\/10.1001\/jamaneurol.2022.4485.","journal-title":"JAMA Neurol"},{"key":"7457_CR13","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","volume":"3","author":"WS Brum","year":"2023","unstructured":"Brum WS, Cullen NC, Janelidze S, Ashton NJ, Zimmer ER, Therriault J, et al. A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases. Nat Aging. 2023;3:1079\u201390. https:\/\/doi.org\/10.1038\/s43587-023-00471-5.","journal-title":"Nat Aging"},{"key":"7457_CR14","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1038\/s41467-024-46603-2","volume":"15","author":"WS Brum","year":"2024","unstructured":"Brum WS, Cullen NC, Therriault J, Janelidze S, Rahmouni N, Stevenson J, et al. A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings. Nat Commun. 2024;15:2311. https:\/\/doi.org\/10.1038\/s41467-024-46603-2.","journal-title":"Nat Commun"},{"key":"7457_CR15","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","volume":"30","author":"NR Barth\u00e9lemy","year":"2024","unstructured":"Barth\u00e9lemy NR, Salvad\u00f3 G, Schindler SE, He Y, Janelidze S, Collij LE, et al. Highly accurate blood test for alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests. Nat Med. 2024;30:1085\u201395. https:\/\/doi.org\/10.1038\/s41591-024-02869-z.","journal-title":"Nat Med"},{"key":"7457_CR16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, et al. Diagnostic accuracy of a plasma phosphorylated Tau 217 immunoassay for alzheimer disease pathology. JAMA Neurol. 2024;81:255\u201363. https:\/\/doi.org\/10.1001\/jamaneurol.2023.5319.","journal-title":"JAMA Neurol"},{"key":"7457_CR17","doi-asserted-by":"publisher","first-page":"e14022","DOI":"10.15252\/emmm.202114022","volume":"13","author":"N Mattsson-Carlgren","year":"2021","unstructured":"Mattsson-Carlgren N, Janelidze S, Bateman RJ, Smith R, Stomrud E, Serrano GE, et al. Soluble P-tau217 reflects amyloid and Tau pathology and mediates the association of amyloid with Tau. EMBO Mol Med. 2021;13:e14022. https:\/\/doi.org\/10.15252\/emmm.202114022.","journal-title":"EMBO Mol Med"},{"key":"7457_CR18","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1002\/alz.13393","volume":"19","author":"PCL Ferreira","year":"2023","unstructured":"Ferreira PCL, Therriault J, Tissot C, Ferrari-Souza JP, Benedet AL, Povala G, et al. Plasma p-tau231 and p-tau217 inform on Tau tangles aggregation in cognitively impaired individuals. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc. 2023;19:4463\u201374. https:\/\/doi.org\/10.1002\/alz.13393.","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"key":"7457_CR19","doi-asserted-by":"publisher","first-page":"e17123","DOI":"10.15252\/emmm.202217123","volume":"15","author":"G Salvad\u00f3","year":"2023","unstructured":"Salvad\u00f3 G, Ossenkoppele R, Ashton NJ, Beach TG, Serrano GE, Reiman EM, et al. Specific associations between plasma biomarkers and postmortem amyloid plaque and Tau tangle loads. EMBO Mol Med. 2023;15:e17123. https:\/\/doi.org\/10.15252\/emmm.202217123.","journal-title":"EMBO Mol Med"},{"key":"7457_CR20","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1212\/wnl.0000000000004643","volume":"89","author":"MJ Grothe","year":"2017","unstructured":"Grothe MJ, Barthel H, Sepulcre J, Dyrba M, Sabri O, Teipel SJ. In vivo staging of regional amyloid deposition. Neurology. 2017;89:2031\u20138. https:\/\/doi.org\/10.1212\/wnl.0000000000004643.","journal-title":"Neurology"},{"key":"7457_CR21","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.jalz.2018.04.011","volume":"14","author":"BJ Hanseeuw","year":"2018","unstructured":"Hanseeuw BJ, Betensky RA, Mormino EC, Schultz AP, Sepulcre J, Becker JA, et al. PET staging of amyloidosis using striatum. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc. 2018;14:1281\u201392. https:\/\/doi.org\/10.1016\/j.jalz.2018.04.011.","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"key":"7457_CR22","doi-asserted-by":"publisher","first-page":"e1538","DOI":"10.1212\/wnl.0000000000010256","volume":"95","author":"LE Collij","year":"2020","unstructured":"Collij LE, Heeman F, Salvad\u00f3 G, Ingala S, Altomare D, de Wilde A, et al. Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology. 2020;95:e1538\u201353. https:\/\/doi.org\/10.1212\/wnl.0000000000010256.","journal-title":"Neurology"},{"key":"7457_CR23","doi-asserted-by":"publisher","first-page":"5434","DOI":"10.1002\/alz.14036","volume":"20","author":"ME Farrell","year":"2024","unstructured":"Farrell ME, Thibault EG, Becker JA, Price JC, Healy BC, Hanseeuw BJ, et al. Spatial extent as a sensitive amyloid-PET metric in preclinical alzheimer\u2019s disease. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc. 2024;20:5434\u201349. https:\/\/doi.org\/10.1002\/alz.14036.","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"key":"7457_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","volume":"79","author":"KA Johnson","year":"2016","unstructured":"Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al. Tau positron emission tomographic imaging in aging and early alzheimer disease. Ann Neurol. 2016;79:110\u20139. https:\/\/doi.org\/10.1002\/ana.24546.","journal-title":"Ann Neurol"},{"key":"7457_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/ana.24711","volume":"80","author":"H Cho","year":"2016","unstructured":"Cho H, Choi JY, Hwang MS, Kim YJ, Lee HM, Lee HS, et al. In vivo cortical spreading pattern of Tau and amyloid in the alzheimer disease spectrum. Ann Neurol. 2016;80:247\u201358. https:\/\/doi.org\/10.1002\/ana.24711.","journal-title":"Ann Neurol"},{"key":"7457_CR26","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","volume":"89","author":"M Sch\u00f6ll","year":"2016","unstructured":"Sch\u00f6ll M, Lockhart SN, Schonhaut DR, O\u2019Neil JP, Janabi M, Ossenkoppele R, et al. PET imaging of Tau deposition in the aging human brain. Neuron. 2016;89:971\u201382. https:\/\/doi.org\/10.1016\/j.neuron.2016.01.028.","journal-title":"Neuron"},{"key":"7457_CR27","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s43587-022-00204-0","volume":"2","author":"J Therriault","year":"2022","unstructured":"Therriault J, Pascoal TA, Lussier FZ, Tissot C, Chamoun M, Bezgin G, et al. Biomarker modeling of alzheimer\u2019s disease using PET-based Braak staging. Nat Aging. 2022;2:526\u201335. https:\/\/doi.org\/10.1038\/s43587-022-00204-0.","journal-title":"Nat Aging"},{"key":"7457_CR28","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1007\/s00259-018-4081-5","volume":"45","author":"SH Cho","year":"2018","unstructured":"Cho SH, Shin JH, Jang H, Park S, Kim HJ, Kim SE, et al. Amyloid involvement in subcortical regions predicts cognitive decline. Eur J Nucl Med Mol Imaging. 2018;45:2368\u201376. https:\/\/doi.org\/10.1007\/s00259-018-4081-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7457_CR29","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","volume":"28","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S, et al. Amyloid and Tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med. 2022;28:2381\u20137. https:\/\/doi.org\/10.1038\/s41591-022-02049-x.","journal-title":"Nat Med"},{"key":"7457_CR30","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jama.2024.13855","volume":"332","author":"S Palmqvist","year":"2024","unstructured":"Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, et al. Blood biomarkers to detect alzheimer disease in primary care and secondary care. JAMA. 2024;332:1245\u201357. https:\/\/doi.org\/10.1001\/jama.2024.13855.","journal-title":"JAMA"},{"key":"7457_CR31","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512\u201327. https:\/\/doi.org\/10.1001\/jama.2023.13239.","journal-title":"JAMA"},{"key":"7457_CR32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jamaneurol.2023.4596","volume":"81","author":"N Mattsson-Carlgren","year":"2024","unstructured":"Mattsson-Carlgren N, Collij LE, Stomrud E, Pichet Binette A, Ossenkoppele R, Smith R, et al. Plasma biomarker strategy for selecting patients with alzheimer disease for antiamyloid immunotherapies. JAMA Neurol. 2024;81:69\u201378. https:\/\/doi.org\/10.1001\/jamaneurol.2023.4596.","journal-title":"JAMA Neurol"},{"key":"7457_CR33","doi-asserted-by":"publisher","first-page":"212","DOI":"10.12779\/dnd.2024.23.4.212","volume":"23","author":"H Jang","year":"2024","unstructured":"Jang H, Shin D, Kim Y, Kim KW, Lee J, Kim JP, et al. Korea-Registries to overcome dementia and accelerate dementia research (K-ROAD): A cohort for dementia research and Ethnic-Specific insights. Dement Neurocogn Disord. 2024;23:212\u201323.","journal-title":"Dement Neurocogn Disord"},{"issue":"2","key":"7457_CR34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1037\/1040-3590.3.2.168","volume":"3","author":"KJ Christensen","year":"1991","unstructured":"Christensen KJ, Multhaup KS, Nordstrom S, Voss K. A cognitive battery for dementia: Development and measurement characteristics. Psychological Assessment: A Journal of Consulting and Clinical Psychology. 1991;3(2):168\u201374. https:\/\/doi.org\/10.1037\/1040-3590.3.2.168.","journal-title":"Psychological Assessment: A Journal of Consulting and Clinical Psychology"},{"key":"7457_CR35","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3346\/jkms.2010.25.7.1071","volume":"25","author":"HJ Ahn","year":"2010","unstructured":"Ahn HJ, Chin J, Park A, Lee BH, Suh MK, Seo SW, Na DL. Seoul neuropsychological screening Battery-dementia version (SNSB-D): a useful tool for assessing and monitoring cognitive impairments in dementia patients. J Korean Med Sci. 2010;25:1071\u20136. https:\/\/doi.org\/10.3346\/jkms.2010.25.7.1071.","journal-title":"J Korean Med Sci"},{"key":"7457_CR36","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7:270\u20139.","journal-title":"Alzheimer\u2019s Dement"},{"key":"7457_CR37","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH, et al. The diagnosis of dementia due to alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimers Dement"},{"key":"7457_CR38","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2214\/ajr.149.2.351","volume":"149","author":"F Fazekas","year":"1987","unstructured":"Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in alzheimer\u2019s dementia and normal aging. AJR Am J Roentgenol. 1987;149:351\u20136. https:\/\/doi.org\/10.2214\/ajr.149.2.351.","journal-title":"AJR Am J Roentgenol"},{"key":"7457_CR39","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496\u2013503. https:\/\/doi.org\/10.1212\/WNL.0b013e31827f0fd1.","journal-title":"Neurology"},{"key":"7457_CR40","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006\u201314. https:\/\/doi.org\/10.1212\/WNL.0b013e31821103e6.","journal-title":"Neurology"},{"key":"7457_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/wnl.47.1.1","volume":"47","author":"I Litvan","year":"1996","unstructured":"Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47:1\u20139. https:\/\/doi.org\/10.1212\/wnl.47.1.1.","journal-title":"Neurology"},{"key":"7457_CR42","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456\u201377. https:\/\/doi.org\/10.1093\/brain\/awr179.","journal-title":"Brain"},{"key":"7457_CR43","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/21678421.2016.1267768","volume":"18","author":"MJ Strong","year":"2017","unstructured":"Strong MJ, Abrahams S, Goldstein LH, Woolley S, McLaughlin P, Snowden J, et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degeneration. 2017;18:153\u201374. https:\/\/doi.org\/10.1080\/21678421.2016.1267768.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degeneration"},{"key":"7457_CR44","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13195-022-01099-0","volume":"14","author":"SJ Kim","year":"2022","unstructured":"Kim SJ, Ham H, Park YH, Choe YS, Kim YJ, Jang H, et al. Development and clinical validation of CT-based regional modified centiloid method for amyloid PET. Alzheimers Res Ther. 2022;14:157. https:\/\/doi.org\/10.1186\/s13195-022-01099-0.","journal-title":"Alzheimers Res Ther"},{"key":"7457_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/rlu.0000000000004937","volume":"49","author":"SJ Kim","year":"2024","unstructured":"Kim SJ, Jang H, Yoo H, Na DL, Ham H, Kim HJ, et al. Clinical and pathological validation of CT-Based regional harmonization methods of amyloid PET. Clin Nucl Med. 2024;49:1\u20138. https:\/\/doi.org\/10.1097\/rlu.0000000000004937.","journal-title":"Clin Nucl Med"},{"key":"7457_CR46","doi-asserted-by":"publisher","first-page":"117","DOI":"10.12779\/dnd.2024.23.3.117","volume":"23","author":"J Kim","year":"2024","unstructured":"Kim J, Jahng S, Kim S, Kang Y. A comparison of item characteristics and test information between the K-MMSE\u2009~\u20092:SV and K-MMSE. Dement Neurocogn Disord. 2024;23:117\u201326. https:\/\/doi.org\/10.12779\/dnd.2024.23.3.117.","journal-title":"Dement Neurocogn Disord"},{"key":"7457_CR47","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, M\u00fcller M. pROC: an open-source package for R and S\u2009+\u2009to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77. https:\/\/doi.org\/10.1186\/1471-2105-12-77.","journal-title":"BMC Bioinformatics"},{"key":"7457_CR48","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1037\/h0026256","volume":"70","author":"J Cohen","year":"1968","unstructured":"Cohen J. Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull. 1968;70:213\u201320. https:\/\/doi.org\/10.1037\/h0026256.","journal-title":"Psychol Bull"},{"key":"7457_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"D Bates","year":"2015","unstructured":"Bates D, M\u00e4chler M, Bolker B, Walker S. Fitting linear Mixed-Effects models using lme4. J Stat Softw. 2015;67:1\u201348. https:\/\/doi.org\/10.18637\/jss.v067.i01.","journal-title":"J Stat Softw"},{"key":"7457_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-4541-9","volume-title":"An introduction to the bootstrap","author":"B Efron","year":"1993","unstructured":"Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman and Hall; 1993."},{"key":"7457_CR51","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Royal Stat Soc Ser B (Methodological). 1995;57:289\u2013300.","journal-title":"J Royal Stat Soc Ser B (Methodological)"},{"key":"7457_CR52","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13024-022-00578-0","volume":"17","author":"ME Murray","year":"2022","unstructured":"Murray ME, Moloney CM, Kouri N, Syrjanen JA, Matchett BJ, Rothberg DM, et al. Global neuropathologic severity of alzheimer\u2019s disease and locus coeruleus vulnerability influences plasma phosphorylated Tau levels. Mol Neurodegener. 2022;17:85. https:\/\/doi.org\/10.1186\/s13024-022-00578-0.","journal-title":"Mol Neurodegener"},{"key":"7457_CR53","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS, et al. Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for alzheimer\u2019s trial selection and disease monitoring. Nat Med. 2022;28:2555\u201362. https:\/\/doi.org\/10.1038\/s41591-022-02074-w.","journal-title":"Nat Med"},{"key":"7457_CR54","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","volume":"80","author":"N Mattsson-Carlgren","year":"2023","unstructured":"Mattsson-Carlgren N, Salvad\u00f3 G, Ashton NJ, Tideman P, Stomrud E, Zetterberg H, et al. Prediction of longitudinal cognitive decline in preclinical alzheimer disease using plasma biomarkers. JAMA Neurol. 2023;80:360\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2022.5272.","journal-title":"JAMA Neurol"},{"key":"7457_CR55","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1093\/brain\/awac329","volume":"146","author":"C Groot","year":"2023","unstructured":"Groot C, Smith R, Stomrud E, Binette AP, Leuzy A, Wuestefeld A, et al. Phospho-tau with subthreshold Tau-PET predicts increased Tau accumulation rates in amyloid-positive individuals. Brain. 2023;146:1580\u201391. https:\/\/doi.org\/10.1093\/brain\/awac329.","journal-title":"Brain"},{"key":"7457_CR56","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1093\/brain\/awad042","volume":"146","author":"CR Jack","year":"2023","unstructured":"Jack CR, Wiste HJ, Algeciras-Schimnich A, Figdore DJ, Schwarz CG, Lowe VJ, et al. Predicting amyloid PET and Tau PET stages with plasma biomarkers. Brain. 2023;146:2029\u201344. https:\/\/doi.org\/10.1093\/brain\/awad042.","journal-title":"Brain"},{"key":"7457_CR57","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s43587-023-00405-1","volume":"3","author":"L Montoliu-Gaya","year":"2023","unstructured":"Montoliu-Gaya L, Benedet AL, Tissot C, Vrillon A, Ashton NJ, Brum WS, et al. Mass spectrometric simultaneous quantification of Tau species in plasma shows differential associations with amyloid and Tau pathologies. Nat Aging. 2023;3:661\u20139. https:\/\/doi.org\/10.1038\/s43587-023-00405-1.","journal-title":"Nat Aging"},{"key":"7457_CR58","doi-asserted-by":"publisher","first-page":"105405","DOI":"10.1016\/j.ebiom.2024.105405","volume":"109","author":"A Feizpour","year":"2024","unstructured":"Feizpour A, Doecke JD, Dor\u00e9 V, Krishnadas N, Huang K, Bourgeat P, et al. Detection and staging of alzheimer\u2019s disease by plasma pTau217 on a high throughput immunoassay platform. EBioMedicine. 2024;109:105405. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105405.","journal-title":"EBioMedicine"},{"key":"7457_CR59","doi-asserted-by":"publisher","first-page":"105046","DOI":"10.1016\/j.ebiom.2024.105046","volume":"102","author":"J Therriault","year":"2024","unstructured":"Therriault J, Ashton NJ, Pola I, Triana-Baltzer G, Brum WS, Di Molfetta G, et al. Comparison of two plasma p-tau217 assays to detect and monitor alzheimer\u2019s pathology. EBioMedicine. 2024;102:105046. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105046.","journal-title":"EBioMedicine"},{"key":"7457_CR60","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","volume":"29","author":"K Horie","year":"2023","unstructured":"Horie K, Salvad\u00f3 G, Barth\u00e9lemy NR, Janelidze S, Li Y, He Y, et al. CSF MTBR-tau243 is a specific biomarker of Tau tangle pathology in alzheimer\u2019s disease. Nat Med. 2023;29:1954\u201363. https:\/\/doi.org\/10.1038\/s41591-023-02443-z.","journal-title":"Nat Med"},{"key":"7457_CR61","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s13195-022-01142-0","volume":"14","author":"J Simr\u00e9n","year":"2022","unstructured":"Simr\u00e9n J, Brum WS, Ashton NJ, Benedet AL, Karikari TK, Kvartsberg H, et al. CSF Tau368\/total-tau ratio reflects cognitive performance and neocortical Tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals. Alzheimers Res Ther. 2022;14:192. https:\/\/doi.org\/10.1186\/s13195-022-01142-0.","journal-title":"Alzheimers Res Ther"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07457-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07457-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07457-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T05:05:37Z","timestamp":1764219937000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07457-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["7457"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07457-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The institutional review board of Samsung Medical Center (No. 2021-02-135) approved this study. All participants provided informed consent to participate in the study, and the data were collected in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Henrik Zetterberg has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has delivered lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).Kaj Blennow has served as a consultant and on advisory boards for Abbvie, AC Immune, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served on data monitoring committees for Julius Clinical and Novartis; has delivered lectures, produced educational materials, and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. Other authors have no conflicts of interest to disclose","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}